Tim Wartenberg joins Vintura as a partner in Germany

03 August 2021 Consultancy.eu 2 min. read
More news on

Dutch healthcare and life sciences consultancy Vintura has added a new partner to its team in Germany. 

Tim Wartenberg brings over 25 years of experience in management consultancy and industry to the consulting firm. After starting his career in the pharmaceutical industry in several marketing and sales roles, he transitioned into consulting in 2003 and ran his own advisory business for eight years, growing the firm to a 15-strong headcount before selling it to a counterpart. 

Since then, he served several major consulting firms in their healthcare and life sciences vertical: EY and Capgemini Invent; Deloitte’s strategy consulting outfit Monitor Deloitte, where he was a partner; and Infosys Consulting, where he was the European Lead of its Life Science practice.

Tim Wartenberg, Partner, Vintura

During this period, he served major pharma clients including Bayer, Novartis, Boehringer Ingelheim, Lonza and Zoetis, supporting them with topics spanning strategy, commercial excellence, market access, processes optimisation, patient advocacy, system implementation, digitisation, and change management. 

He will now leverage this experience to help Vintura grow its presence in the German landscape. Founded in 2000, the consulting firm currently has around 40 consultants, the majority of which work from its office in home country the Netherlands. Vintura has however in recent years expanded into the UK and Germany, and is eyeing further growth in these two markets. 

Commenting on the appointment in neighbouring Germany, Netherlands-based Vintura partner Bas Amesz said: “We are glad to have Tim join our team. He truly reflects our drive to create remarkable impact in healthcare together. Under his leadership we are convinced the Munich office will further expand and flourish.” 

Clients of Vintura include the likes of AbbVie, Amgen, Ferring, Genzyme, Ipsen, Janssen, Johnson & Johnson, Medtronic, Roche, Sanofi and Takeda.